Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon

Kyle LaHucik

Biotech Correspondent

Eight months after missing the primary and secondary endpoints on a mid-stage test of its ALS drug, Clene Nanomedicine is back with new data showing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

MD Anderson targets $250M for second cancer biotech fund

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Strand Therapeutics reports promising start for mRNA cancer therapy

InflaRx cans Gohibic development after skin disease trial stopped for futility

FDA leadership preps for summer biopharma listening tour across six cities

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Dark-horse ALS play­er touts open-la­bel sur­vival da­ta af­ter mid-stage flop, with plat­form study due soon

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

MD An­der­son tar­gets $250M for sec­ond can­cer biotech fund

No­var­tis won bid­ding war for kid­ney drug as Reg­u­lus' top three ex­ecs ex­pect to make over $100M com­bined

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

FDA lead­er­ship preps for sum­mer bio­phar­ma lis­ten­ing tour across six cities

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon

MD Anderson targets $250M for second cancer biotech fund

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Strand Therapeutics reports promising start for mRNA cancer therapy

InflaRx cans Gohibic development after skin disease trial stopped for futility

FDA leadership preps for summer biopharma listening tour across six cities

From weeks to days: how Aizon Intelligent Agents transform pharma validation